Xconomy

SEPTEMBER 15, 2016

The Connect Innovation Report found that 405 software, technology, and life sciences startups were created last year in San Diego County. Innovation Companies in San Diego (Courtesy Connect Innovation Report).

San Diego 40

San Diego Report High Tech Study 40

socalTECH

SEPTEMBER 24, 2021

San Diego-based biotech Kintara says it is raising $15.0M in a common stock and warrant offering from unmaned "healthcare-focused institutional investors". The company--which is novel cancer therapies for patients who are failing, or are resistant to, current treatment regimens--currently trades on the Nasdaq as KTRA. Wainwright & Co.

San Diego 113

San Diego .Net Study Acquisition 113

socalTECH

JULY 28, 2021

San Diego-based immunology startup Aristea Therapeutics says it has raised $63M in a Series B financing round, which was led by Fidelity Management & Research Company, LLC, along with Novo Holdings A/S, plus Arena Pharmaceuticals and funds managed by Tekla Capital Management, LLC. Mackay, Ph.D.

San Diego 100

San Diego Study Research Capital 100

socalTECH

JUNE 24, 2019

San Diego-based biopharmaceuticals startup AFYX Therapeutics announced this morning that it has raised $13M in a convertible loan financing. The company is currently in an ongoing, Phase 2B study. The note came from Sofinnova Ventuers, which led the investment, and also included Nova Seeds and Lundbeckfonden Emerge.

Study 113

Study San Diego Platform Invest 113

socalTECH

AUGUST 31, 2021

San Diego-based "ARS Pharmaceuticals, which is developing an epinephrine nasal spray designed to better treat severe allergic reaction, said today that it has raised $55M in a Series D funding. The funding was led by SR One, and also included RA Capital Management, an un-named US healthcare-focused fund, and Deerfield Management.

Funding 113

Funding San Diego Study Activity 113

socalTECH

FEBRUARY 13, 2013

San Diego-based DriveCam , the developer of driver monitoring systems for commercial automobile fleets, said this morning that it has received a strategic investment from Volvo Group. According to DriveCam, Volvo Group Venture Capital made the strategic investment, and becomes a minority shareholder in the company.

Invest 153

Invest San Diego Study Venture Capital 153

socalTECH

NOVEMBER 7, 2018

San Diego-based Mirium Pharmaceuticals , which is developing treatments for rare liver diseases, announced on Wednesday morning that it has raised $120M in a Series A funding round. The company says it recently had a successful Phase 2b study. READ MORE>>.

San Diego 147

San Diego Study Capital Funding 147

socalTECH

APRIL 1, 2020

San Diego-based Aspen Neuroscience , a biotechnology company developing treatments for Parkinson disease, said it has raised $70M in a Series A funding round. The funding was led by OrbiMed, and also included ARCH Venture Partners, Frazier Healthcare Partners, Domain Associates, Section 32, and Sam Altman.

San Diego 113

San Diego Screening Study Course 113

Xconomy

APRIL 11, 2017

As part of the financing, Kalamazoo-based Octeta Therapeutics has been rechristened Cirius Therapeutics, and three San Diego-based biotech executives are stepping into key executive roles. All three were former Laguna Pharmaceuticals executives who spent the past 16 months scouting for Frazier as entrepreneurs-in-residence.

Study 55

Study San Diego Entrepreneur Venture Capital 55

SoCal Tech Calendar

OCTOBER 17, 2012

Tuesday, October 23, 2012 -- The San Diego Tech Coast Angels present Early-Stage Valuation. Program Overview: This interactive workshop educates and empowers angel investors, entrepreneurs, and others interested in access to capital on a variety of ways to value pre-revenue companies. Email linda@techcoastangels.com.

Tech Coast Angels 113

Tech Coast Angels Case Study San Diego Study 113

socalTECH

NOVEMBER 11, 2010

San Diego-based Aires Pharmaceuticals , a developer of treatments for pulmonary arterial hypertension, said this morning that it has raised $20M in a Series B funding round. The round was led by MPM Capital, and also included prior investor ProQuest Investments. MPM's Dr. William Greene joins the board as part of the funding.

San Diego 154

San Diego Venture Capital Study Capital 154

socalTECH

JANUARY 5, 2016

San Diego-based Halozyme Therapeutics , the publicly held cancer therapeutics developer, has entered into a $150M credit agreement, the company said this morning. The debt funding comes from Pharmakon Advisors and Athyrium Capital Management. READ MORE>>.

Study 100

Study San Diego Capital Funding 100

Xconomy

APRIL 22, 2019

Swiss pharma giant Novartis has invested $75 million in a $142 million Series C round for San Diego-based Poseida, which is one of several companies developing what is meant to be a one-time, long-lasting treatment for multiple myeloma. Multiple myeloma affects about 300,000 Americans every year.

San Diego 83

San Diego Study Funding Invest 83

socalTECH

NOVEMBER 30, 2010

San Diego-based Histogen , a developer of regenerative medicine products, announced today that it has raised $10M in a Series A financing round. The financing came from private investors, including Secure Medical, Leonard Lavin, Lordship Ventures, and Angus Mitchell. READ MORE>>.

San Diego 173

San Diego Study Venture Capital Product 173

Xconomy

NOVEMBER 3, 2017

Thynk Capital founder and principal Jim Plante also is Klotho’s founder and CEO. Plante is a technology industry veteran in San Diego who has served as the CEO of Bel-Tronics, and as the founding CEO of SmartDrive Systems and Pathway Genomics. Studies in mice have.

San Diego 85

San Diego Study Capital Technology 85

socalTECH

JUNE 23, 2010

San Diego-based Nereus Pharmaceuticals , a firm developing drugs for the treatment of lung cancer, said Tuesday that it has raised another $20M in funding and commitments from its venture backers. Tags: nereus pharmaceuticals lifescience venture capital cancer biotech biopharma biopharmaceuticals.

San Diego 140

San Diego Venture Capital Study Funding 140

socalTECH

AUGUST 30, 2010

San Diego-based Otonomy , a biopharmaceuticals firm developing products to treat disorders of the inner and middle ear, announced today that it has raised $38.5M The round was led by Novo Ventures and RiverVest Venture Partners, and also includes Domain Associates, TPG Biotech, and Avalon Ventures.

Avalon 150

Avalon San Diego Venture Capital Study 150

Xconomy

DECEMBER 20, 2018

New biopharma company Aristea Therapeutics has raised $15 million from Novo Holdings, the Danish investment company, and secured global rights to an investigational AstraZeneca drug that’s ready for Phase 2 study. The San Diego, CA, company made its public debut this week after starting up quietly earlier this year.

Develop 67

Develop Development San Diego Study 67

socalTECH

NOVEMBER 11, 2010

San Diego-based biopharmaceuticals firm Ceregene announced this morning that it has raised $11.5M The round was co-led by Hamilton Bioventures and Alta Partners, and also included MPM Capital and Investor Growth Capital. Tags: ceregene venture capital lifescience parkinsons disease biopharma. READ MORE>>.

San Diego 124

San Diego Venture Capital Study Capital 124

socalTECH

JANUARY 27, 2016

San Diego-based biopharmaceuticals developer Halozyme Therapeutics said yesterday that it has raised $150M in royalty-backed, debt financing. The financing came from Pharmakon Advisors and Athyrium Capital Management. According to the company, the funding will go towards a Phase 3 cancer study in cancer patients.

Funding 100

Funding San Diego Study Capital 100

Xconomy

FEBRUARY 15, 2017

For these reasons, fatty liver disease is often called a “silent disease,” says Ariel Feldstein, a gastroenterologist at the University of California San Diego. Feldstein has been studying the liver for nearly 20 years, and his research now forms the basis of a newly launched company called Jecure Therapeutics.

UCSD 64

UCSD Press San Diego Class 64

Xconomy

AUGUST 1, 2017

Ciara Kennedy, who succeeded Mike Grey as Amplyx CEO late last year, said in an interview with Xconomy that the company plans to report results of its Phase 1 study at IDWeek, the annual infectious diseases conference that is set for early October in San Diego. But raising $67.

San Diego 67

San Diego Study Conference Report 67

Xconomy

DECEMBER 7, 2017

Proceeds will be used to advance Metacrine’s lead drug candidate, MET409, into first-in-human studies during the first half of 2018. Initial studies should be completed by the end of the year, the San Diego-based company said.

San Diego 49

San Diego Study Develop Development 49

socalTECH

DECEMBER 6, 2012

San Diego-based Avelas Biosciences has raised $7.65M in a Series A funding round, which it says will go towards clinical studies for its technology for real-time tumor visualization. The funding came from Avalon Ventures. Avelas is developing technology for visualizing cancerous lymph nodes in breast cancer patients.

Avalon 138

Avalon San Diego Study Technology 138

Xconomy

SEPTEMBER 25, 2017

After launching a study to identify how tech hubs work, the leader of a nonprofit consortium created to boost Southern California’s startup ecosystem says he is focusing on three initiatives to supercharge the seven-county SoCal region as a hotbed for innovation. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Southern California 61

Southern California San Diego SoCal Incubator 61

socalTECH

APRIL 15, 2019

San Diego-based Wheels (www.takewheels.com) was co-founded by Jon and Josh Viner, who were the co-founders of Wag, where they raised nearly $400M in venture capital. Wheels currently operates in Los Angeles and San Diego. Josh Viner: Wheels is live in Los Angeles and San Diego. What is Wheels?

San Diego 113

San Diego Startup Study Los Angeles 113

socalTECH

MAY 25, 2012

San Diego-based biopharmaceuticals firm Sangart has raised $50M in a Series G funding round, the company announced Thursday, bringing its total venture funds raised to $280M. The firm said the funding will go towards advancing development of its medicines, which are currently in Phase 2b studies. READ MORE>>.

San Diego 133

San Diego Study Funding Develop 133

socalTECH

MARCH 12, 2012

San Diego-based HemaQuest Pharmaceuticals said today that it has raised $13M in a Series B funding. The new funds will go towards a Phase 2b clinical study to apply its compound to patients with sickle cell disease. READ MORE>>.

San Diego 124

San Diego Study Funding Develop 124

socalTECH

JANUARY 4, 2012

San Diego-based Elevation Pharmaceuticals , which is developing treatment for patients with chronic obstructive pulmonary disease (COPD), said this morning that it has closed on a $30M, Series B funding round. The firm said the funds will help the firm complete all activities to reach Phase 3 studies by the end of 2013.

San Diego 133

San Diego Study Activity Funding 133

Xconomy

JULY 20, 2016

First came Inception Sciences , a holding company for spinning out biotech startups established by Versant Ventures and Peppi Prasit, the veteran San Diego drug developer. All of the company’s funding so far has come from Sofinnova Ventures, and Mike Powell, a Sofinnova general partner in San Francisco, is board chairman.

San Diego 40

San Diego Avalon Outsource Development Newsletter 40

Xconomy

AUGUST 17, 2016

It was joined by two other new backers, Ervington Investments and Alexandria Venture Investments, and previous investors WuXi Healthcare Ventures, Bregua Corp., and San Diego’s Avalon Ventures. Inbio Ventures, a venture capital management company, represented Pharmstandard in the deal.

Avalon 40

Avalon San Diego Study Invest 40

Xconomy

JANUARY 11, 2017

While we’re looking at venture deal numbers from the past year , let’s consider the education technology industry, which isn’t broken out by sector in the general reports I’ve seen. A recent study by EdSurge , an edtech information firm, shows venture funding for U.S. education tech companies totaled $1.03

Funding 40

Funding Education Venture Capital Study 40

Both Sides of the Table

APRIL 13, 2011

I owe ya’ a 20 minute call (or in person next time I’m in San Diego). Yeah, that was when I changed for me…” “…there was so much positive feedback on demystifying this one element of venture capital. Deal evaluations the Foundry way, which continues into a great discussion about VC decision-making processes.

Venture Capital 288

Venture Capital Startup Technical Review Software Review 288

Xconomy

MARCH 2, 2020

The company’s lead drug, ORIC-101, is under evaluation in Phase 1b studies in combination with enzalutamide (Xtandi) in prostate cancer and. ORIC is an acronym for “overcoming resistance in cancer.” Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Study 90

Study Research Funding Marketing 90

Xconomy

SEPTEMBER 28, 2018

While other groups tested other fish oils and found no evidence of concrete cardiovascular benefits , Amarin pressed on with a massive study, bleeding cash for years. Amarin said this week that the REDUCE-IT study showed Vascepa lowered the risk of heart disease, marking a. The strategy seems to have paid off.

News 73

News Study Press Sales 73

socalTECH

FEBRUARY 19, 2016

San Diego-based eFFECTOR Therapeutics , which is developing gene translation technology to help in the treatment of cancer, has boosted its Series B funding to $56M, the company said Friday. The company--which raised $40M in the round back in December--said the new funding came from Sectoral Asset Management. Maha Katabi, Ph.D.,

San Diego 100

San Diego Funding Capital Help 100

socalTECH

OCTOBER 19, 2016

The second thing I learned as a VC, is that data paralyzes people. VC is definitely a dream job. In 2014, we did an IRB approved study when I was doing this for 30 to 40 percent of my time, where I learned three things. What made you decide to go from a full time GP at Maveron to the hard work of running a company?

Coach 100

Coach Startup Study Venture Capital 100